Vicept Therapeutics Inc., of Malvern, Pa., said results from a Phase II trial testing the dose-response relationship of two concentrations of V-101, a topical cream for treating Type I rosacea demonstrated a statistically significant improvement (p < 0.01) in the primary endpoint, defined as a reduction in facial erythema over a 12-hour period vs. placebo cream. V-101 also demonstrated a safety profile similar to placebo.